Connect with us


5 ‘value investing’ Sin Stocks of 2021- An Investor Telegraph Exclusive .



We present to you our analyses of five sin stocks which we strongly believe are  value investing stocks that appear to be trading for less than their intrinsic or book value and will give good double-digit returns in 2021

General Dynamics (NYSE: GD)

It’s been a tough year for defense stocks, and General Dynamics (NYSE: GD) in particular, as investors weighed the ramifications of the looming U.S. presidential election and the pandemic’s impact on aerospace.

General Dynamics had a great November, but the stock still has a lot of room to run. The company was an underperformer well before the pandemic, weighed down over the last few years by a business jet down cycle that has proven stubborn.

Looking ahead to 2021, General Dynamics’ signature military platform, the Columbia submarine, is a top Pentagon priority. And after a decade of slow sales, the nation’s business jet fleet is aging, which should set up Gulfstream sales to recover as the pandemic fades.

The share might correct a bit at around $150 but will gather momentum for certain in 2021

Vista Outdoor (NYSE: VSTO)

Vista Outdoor is the parent company to many ammunition makers, including Federal Ammunition.

The share had more than tripled in 2020 as revenue jumped 29% in its most recent quarter. For the quarter ended Sept. 27, 2020, Vista said sales in shooting sports rose 26% compared to the prior-year period and jumped 35% in its outdoor-products category. This led to a free cash flow of $190 million

With the pandemic still raging, and the incoming president likely to spark demand for ammunition, Vista looks poised for further gains.

A price od $ 25 is a good investment

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is one of two cannabinoid-focused pharmaceutical companies and the most ‘in’  stocks to buy.

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) focuses on transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, such as Fragile X syndrome and autism spectrum disorder, among others.

At $ 3 -4 levels, it is a value investment


KBR, Inc. is an American engineering, procurement, and construction company, achieved carbon neutrality in its operations and business travel worldwide in 2019,l two years ahead of schedule by strengthening its internal sustainability efforts and examining its carbon footprint.

While the historical EPS growth rate for KBR is 17.8%, the company’s EPS is expected to grow 0.9% this year,

Right now, KBR has a S/TA ratio of 1.11, which means that the company gets $1.11 in sales for each dollar in assets.

Refuting analysts’ views that it may be overpriced at $ 30, we expect the company to perform much better than last year.

Tilray ( NASDAQ: TLRY)

Tilray’s medical cannabis business is not just experiencing growth but also is gaining international expert recognition — which is evident from the recent positive reviews it received for its products used in a clinical study.

Tilray went public at $17 a share in 2018, months ahead of Canada’s legalization of recreational cannabis use.

All experts are of the opening that the stock is overvalued but one cannot ignore the fact that its recent third quarter, which ended Sept. 30, the company saw a decline in total cannabis revenue, but international medical sales were up.

Tilray’s strategies for the future sound promising, but until the strategies bear fruit, Tilray is still a risky investment.

Its lukewarm third-quarter results didn’t help its stock, either, which is down a whopping 50% so far this year. But news of a potential merger and at a price of $ 8 a share, it is a value investment that will give good returns.



Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *